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Under stress conditions such as infection or inflammation the body rapidly needs to generate new 
blood cells that are adapted to the challenge. Haematopoietic cytokines are known to increase output 
of specific mature cells by affecting survival, expansion and differentiation of lineage committed 
progenitors1,2 but it has been debated whether long-term haematopoietic stem cells (HSC) are 
susceptible to direct lineage-specifying effects of cytokines. Although genetic changes in transcription 
factor balance can sensitize HSC to cytokine instruction3, the initiation of HSC commitment is 
generally thought to be triggered by stochastic fluctuation in cell intrinsic regulators such as lineage 
specific transcription factors4,5,6,7, leaving cytokines to ensure survival and proliferation of the progeny 
cells8,9. Here we show that M-CSF, a myeloid cytokine released during infection and inflammation, can 
directly induce the myeloid master regulator PU.1 and instruct myeloid cell fate change in HSC, 
independently of selective survival or proliferation. Video imaging and single cell gene expression 
analysis revealed that stimulation of highly purified HSC with M-CSF in culture resulted in activation 
of the PU.1 promoter and an increased number of PU.1+ cells with myeloid gene signature and 
differentiation potential. In vivo, high systemic levels of M-CSF directly stimulated M-CSF receptor 
dependent activation of endogenous PU.1 protein in single HSC and induced a PU.1 dependent 
myeloid differentiation preference. Our data demonstrate that lineage specific cytokines can act 
directly on HSC in vitro and in vivo to instruct a change of cell identity. This fundamentally changes 
the current view of how HSC respond to environmental challenge and implicates stress-induced 
cytokines as direct instructors of HSC fate. 
 
Lineage specific cytokines such as macrophage colony stimulating factor (M-CSF/CSF-1), can be strongly induced during physiological stress or infection10,11. and potently increase the production of mature cells from lineage-committed progenitors1,2. According to the prevailing model, however, they are generally not believed to directly influence differentiation decisions of haematopoietic stem cells (HSC)9,12,13. Cell fate choice of HSC has traditionally been explained by stochastic models14. In this view transcriptional noise15 and random variations in competing lineage determining transcription factors lead to cross-antagonistic switches that initiate lineage choice4,5,6,7, whereas cytokines are thought to only act on the resulting progeny cells by stimulating their survival and proliferation8,9. A key example of such a master regulator is the transcription factor PU.1 that induces myelo-monocytic differentiation16,17. It is generally unknown whether external signals could drive the initial activation of such intrinsic master regulators. Since HSC deficient for the transcription factor MafB are sensitized to PU.1 activation in response to M-CSF3, we have investigated whether high systemic M-CSF levels could induce PU.1 and instruct myelo-monocytic fate in wt HSC without prior modification of transcription factor balance.  We observed that lipopolysacharide (LPS), a strong mimetic of bacterial infection stimulating high systemic levels of M-CSF11 (sup.fig.1a), induced an up-regulation of GFP in long term HSC (CD117+sca+Lin-CD135-CD34-CD150+) of PU.1-GFP reporter mice18 (sup.fig.1b,c). Consistent with the expression of the M-CSF receptor (M-CSFR) in HSC (sup.fig.2)3,19, direct intravenous injection of recombinant M-CSF also induced significantly increased PU.1 activation in HSC after 16h (fig.1a,b). The treatment caused no significant change in M-CSFR or MafB expression (sup. fig.3), arguing against selection of myeloid primed HSC with high M-CSFR or low MafB levels. M-CSF also induced no change in the proportion of CD150hi HSC, reported to have myeloid lineage bias20, in GFP-positive or –negative HSC (sup.fig.4a-c) and activated PU.1 to a similar extent in CD150hi HSC (fig.1c) as in total HSC (fig.1a,b). Finally cultured CD150hi HSC revealed no proliferation or survival advantage in the presence of M-CSF (sup.fig.5a). Together these data argued against selective amplification or survival of a pre-existing HSC sub-population and indicated that M-CSF could newly induce PU.1 expression in HSC.   As shown in fig.1d, the M-CSF effect on stem cells was direct and specific, since FACS purified HSC showed increased PU.1 expression after 16h in culture with M-CSF but not with GM-CSF or G-CSF, cytokines that may also be released during infection21. The observed changes in gene expression cannot be explained by M-CSF dependent selection of PU.1+ cells, as video-microscopy of cultured HSC showed no proliferation or survival advantage in M-CSF and PU.1 was induced before onset of cell division (sup.fig.5,6). Continuous observation of individual GFP-negative sorted HSC from PU.1-GFP 
mice by video imaging confirmed that M-CSF could induce PU.1 expression in previously PU.1 negative cells (fig.2.a-c, sup.Video1-3). We recorded the fate of HSC between 18 hours and 42 hours of culture, when both the induction of PU.1 in previously negative cells and the division of PU.1+ cells could theoretically occur. At the end of the 24h observation period over two-fold more PU.1+ cells had developed in M-CSF than under control conditions (fig.2d) and backtracking the origin of these cells revealed that all PU.1+ cells were derived from previously PU.1 negative cells, but none from divisions of PU.1+ cells. Although the absence of PU.1+ cell division may be partially due to the phototoxic effects of GFP excitement 22,23, we could conclude that the observed increase in PU.1+ cells was entirely due to M-CSF induced activation of the PU.1 reporter. These commitment events of PU.1 activation occurred 8 hours earlier and at a higher rate over the whole observation period in the presence of M-CSF (fig.2e). Our results indicated that M-CSF could directly increase PU.1 promoter activation in single, previously PU.1 negative HSC.   To further investigate whether M-CSF induced PU.1 activation changed the cell identity of individual HSC we analyzed the mRNA expression profile of single cells by nanofluidic real time PCR on FluidigmTM dynamic arrays. Consistent with their stem cell identity almost all freshly isolated HSC expressed stem and progenitor cell associated genes and about half expressed either no (lin-) or multiple lineage specific genes (mix). The remainder showed mainly megakaryocytic (Meg), megakaryocytic-erythroid (MegE) or myeloid lineage priming (fig.3a, sup.fig.7). Culture for 16h without M-CSF led to an increased number of cells with a mixed lineage profile at the expense of Meg and lin- profiles (fig.3b, sup.fig.8). By contrast, culture in the presence of M-CSF induced a strong increase of cells with a myeloid gene expression signature (fig.3c, sup.fig.9, sup.table1). Consistent with the video microscopy results the increase in myeloid gene expression was associated with a doubling of the number of PU.1+ cells (fig.3d). Interestingly, this increase was entirely due to PU.1+ cells with a myeloid signature that did not express genes from any other lineage. By contrast, the number of PU.1+ cells that also expressed non-myeloid genes remained approximately constant (fig.3d). Together this indicated that M-CSF induced PU.1+ cells had assumed a myeloid cell identity. To evaluate whether this change in gene expression reflected a functional myeloid lineage choice in vivo we compared the differentiation potential of unstimulated PU.1- HSC to PU.1- and PU.1+ HSC after in vivo priming with M-CSF (fig.3e). Progenitor analysis in the spleen 2 weeks after transplantation of these populations revealed a higher ratio of granulocyte/macrophage progenitors (GMP) to megakaryocytic/erythroid progenitors (MEP) developing from PU.1+ HSC than from PU.1- HSC (fig.3f,g). We observed a similar increase in myeloid differentiation potential for PU.1+ cells derived from M-CSF stimulated PU.1- HSC 
in culture (sup.fig.10a-d). Together these data showed that M-CSF induced PU.1 led to a myeloid cell fate change in single HSC.   To further investigate, whether M-CSF could also induce a cell fate change of individual HSC in vivo, we transplanted CFSE-labelled HSC into the spleen, a site of extra-medullary haematopoiesis with adapted stem cell niches3,24, and analyzed expression of endogenous PU.1 protein by immuno-fluorescence in single HSC after 24h (fig.4a). Whereas the vast majority of HSC were PU.1 negative immediately after transplantation, nearly all had activated PU.1 after transfer into spleens of LPS challenged hosts (fig.4b,c). This effect was principally dependent on M-CSF signalling as a blocking antibody against the M-CSF receptor25 strongly inhibited PU.1 activation. Furthermore, direct injection of recombinant M-CSF resulted in a similar strong induction of PU.1 in the transplanted HSC (fig.4b,c). This effect appeared to be entirely cell autonomous, as M-CSF receptor deficient (M-CSFR-/-)26 HSC showed no higher activation of PU.1 in M-CSF stimulated than control recipients (fig.4d,e). Similarly, small molecule inhibitors of the M-CSFR or PI3K, ERK and SRC kinases that signal downstream of the receptor27 also prevented induction of PU.1 (fig.4f), consistent with the stimulation of transcriptional activators of the pu.1 gene by these pathways (sup. discussion). Furthermore, transplantation of in vivo M-CSF primed CD45.2 HSC into sub-lethally irradiated CD45.1 recipients revealed an increased ratio of GMP to MEP progenitors in the spleen after 2 weeks (fig.4g, sup.fig.11a,b) and an increased myeloid to lymphoid cell ratio in peripheral blood after 4 weeks (sup.fig.11c). In competitive transplantation assays M-CSF primed HSC also showed a myeloid advantage compared to platelet and lymphoid contribution at 4 weeks in the blood that re-equilibrated after 6 weeks and did not compromise long-term multi-lineage contribution (fig.4h, sup.fig.12). Finally, this myeloid differentiation preference of M-CSF primed HSC could be abolished by deletion of PU.1 (fig.4i, sup.fig.13). Together these results indicated that M-CSF could directly instruct a change in cell identity of single HSC in vivo that resulted in a reversible, PU.1-dependent myeloid differentiation preference.  Our results show that under haematopoietic stress conditions of infection high systemic levels of M-CSF can directly instruct myeloid gene expression and differentiation preference of HSC. This challenges both the current view of cytokine action and how HSC make differentiation decision. Whereas cytokines are commonly thought to act on lineage-committed progenitors, we here show that stem cells are direct targets of lineage instruction by cytokines. HSC have been shown to proliferate in response to signals characteristic of bacterial28 or viral infections29 but without changing lineage specific gene expression or differentiation potential. In line with the prevailing paradigm of selective cytokine action it has been proposed that distinct stem cell subtypes could have a selective advantage 
in response to different stimuli30. Such a mechanism is difficult to distinguish from instructive mechanisms on a population basis. We have therefore employed multiple assays of single cell analysis in culture and in vivo in a time window before the onset of cell division to distinguish induced changes of lineage specification from selective mechanisms. These data indicate that M-CSF can directly change stem cell identity by activation of the myeloid master regulator PU.1 on the promoter, message and protein level, independently of selective survival or proliferation. The multi-lineage priming of gene expression in haematopoietic stem cells has generally been interpreted as indication that initial cell fate decisions are driven solely by stochastic fluctuations in the balance of lineage specific transcription factors4,5,6,12,13. Our data now indicate that cytokines can not only amplify random choices but also directly activate key regulators of lineage specification such as PU.1 to instruct lineage output of haematopoietic stem cells. Cytokines released during specific challenges may thus directly shunt the differentiation choice of HSC to an insult tailored output of progeny. This discovery may also provide new opportunities for the beneficial manipulation of stem cell fate under pathological or transplantation conditions.  
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Methods summary  Flowcytometry, bone marrow transplantation and in vivo immunofluorescence of HSC were performed essentially as described3. Single cell nano-fluidics-based real-time PCR was performed using a BioMarkTM HD system and 96.96 dynamic arrays (Fluidigm, CA, USA) and videomicroscopy analysis followed proposed standards23. Details of procedures and reagents are described in Supplementary Methods. 
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Figure legends   
Fig.1 M-CSF activates the myeloid master regulator PU.1 in HSC a-c)Representative FACS profile (a) and quantification of GFP expression in HSC (b) or CD150hi HSC (c) of PU.1-GFP reporter mice 16h after control (PBS) or M-CSF injection. ***p=0,009; **p=0,03.  d) Quantitative RT-PCR analysis of PU.1 expression normalized to GAPDH expression (R.U.) in sorted HSC after 16h culture in the absence or presence of M,CSF, GM-CSF or G-CSF. Error bars show standard deviation of duplicates.  
Fig.2 Continuous video-imaging of PU.1+ cell generation from individual PU.1 negative HSC. a) GFP-fluorescence intensity at 10 minute intervals (dots) and sliding median (lines) over 12h observation time of 3 individual GFP negative sorted HSC from PU.1-GFP reporter mice after 18h in M-CSF culture, representative of cells quantified in fig.2e (n=39). Green: cells activating GFP, black: cell remaining GFP negative. b) Still photos taken at times indicated by symbols in a) of fields with 2 representative HSC (cells A,B) showing activation of PU.1 at different time points. Cell C was outside of the shown field. c) Still photos taken at 40 min intervals over 8h of 3 representative HSC in M-CSF culture without (cell C) or with activation of PU.1 (cells A,D), representative of cells quantified in fig.2e (n=39). Complete videos are shown in Sup.Video1-3.  d) Quantification of PU.1+ cells derived from PU.1 negative HSC (committed cells) with (n=39) or without M-CSF (n=42) as percentage of total cells after 24h observation period. *p < 0.1.  e) Timing of PU.1 activation in PU.1 negative HSC of cells shown in d) over 24h observation period.  
Fig.3 M-CSF activates PU.1 and instructs myeloid identity in single HSC  a-c) Gene expression analysis of single cells (rows) for lineage or stem cell representative genes (columns) using duplicate nano-fluidic real time PCR on FluidigmTM array for freshly isolated HSC (a) or after 16 hours of culture in the absence (b) or the presence of M-CSF (c). Genes are grouped by lineage indicated on top and individual cells were clustered according to lineage specific, mixed or lineage negative gene expression profiles shown in bar and pie diagrams on the right. Full gene list and blow up in sup.fig. 7-9. **p= 0.04, n=41,45,45.  d) Individual PU.1+ cells with a myeloid gene expression profile (blue) or expressing other lineage genes (white) as a percentage of total cells. *** p=0.009 (0h), and 0,005 (-M-CSF). 
e) Experimental design for transplantation of sorted PU.1- and PU.1+ HSC from in vivo M-CSF primed CD45.2 PU.1-GFP mice into sub-lethally irradiated CD45.1 recipients and analysis of progeny cells after 2 weeks in the spleen (sup.fig.14). f,g) Representative FACS profiles (f) and quantification of the ratio (g) of donor GMP and MEP progenitors derived from transplanted PU.1- or PU.1+ HSC before or after M-CSF stimulation in 
vivo. **p=0.05, ***p=0.01, n=4,8,4. 
 
Fig.4. M-CSF directly induces endogenous PU.1 protein in single HSC in vivo and stimulates a reversible, PU.1-dependent myeloid differentiation preference. a) Experimental design of HSC transplantation into spleens of LPS or M-CSF stimulated hosts and typical immuno-fluorescence detection of PU.1 in CFSE-labelled HSC 24h after transplantation for two representative PU.1+ and one PU.1- cell. DAPI, nuclear stain.  b,c) Representative immuno-fluorescence images (b) and percentage (c) of PU.1+ HSC immediately (0h) or 24h after transplantation into LPS stimulated host with isotype control (IC) or anti-M-CSF receptor blocking antibody (AFS98), or into M-CSF injected hosts. (n>30). d,e) Representative immuno-fluorescence images (d) and percentage (e) of PU.1+ cells immediately (0h) or 24h after transplantation of wt or M-CSFR-/- HSC into mock or M-CSF stimulated hosts. (n>50). f) Percentage of PU.1+ cells 24h after transplantation of HSC into M-CSF stimulated hosts in the absence or presence of kinase inhibitors for M-CSFR (GW2580), PI3K (LY294002), ERK/MAPK (PD98059) and SRC (SU6656). (n=50). g)  Ratio of donor GMP to MEP progenitors in the spleens of sub-lethally irradiated recipients 2 weeks after transplantation of in vivo M-CSF primed or control HSC. Experimental design is shown in sup.fig.11.  ***p=0.003, n=8,9. h) Donor contribution to blood of competitively reconstituted mice 4 weeks and 6 weeks after transplantation of M-CSF primed or control HSC, expressed as ratio of CD11b+ myeloid cells to platelets or CD19+ lymphoid cells. Experimental design, representative FACS profiles and quantification of contribution to individual lineages in sup.fig.12.  ***p=0.01, n=10,6, *p=0.07, n=6,4.  i) Donor contribution to Mac+ myeloid cells in the spleen of sub-lethally irradiated recipients 2 weeks after transplantation of control or M-CSF primed HSC with control (fl/fl) or deleted (∆/∆) PU.1 alleles. **p=0.05, n=6,4,5.   
Methods  
Mice  CD45.1 and C57Bl/6 mice were obtained from Charles River. PU.1-GFP 31 M-CSFR-/-27 and PU.1fl/fl 32 mice have been described. Age- and sex-matched CD45.1 recipients that were reconstituted as described3 with CD45.2 foetal liver from wt or M-CSFR-/- embryos27 and PU.1fl/fl or PU.1fl/fl::MxCre bone marrow, were used to isolate CD150+ CD34- KSLF HSC not earlier than 8 weeks after reconstitution. For in vivo injections the 10µg/mouse M-CSF, 5mg/kg LPS (055:B5 E. coli) or sorted cells were injected in 100µl of PBS into the retro-orbital sinus. For HSC transplantation 400 CD150+ CD34- KSLF HSC were sorted from CD45.2 mice and mixed with 100.000 Lin+ Sca- CD45.1 carrier cells prior to injection into sub-lethally irradiated (4,5 Gy) CD45.1 recipient mice. For competitive transplantations, 1300 CD150+,CD34-KSLF HSC were isolated 16h after control or 10µg M-CSF injection from actin-GFP CD45.2 mice33, mixed with equal numbers of CD45.2 competitor HSC and injected with 300.000 Lin+ Sca- RC-lysed CD45.1 carrier cells into sub-lethally irradiated (4.5 Gy) CD45.1 recipients. Contribution to platelets, CD19+ B-cells and CD11b+ myeloid cells was analysed after 4 and 6 weeks in the blood from mice with at least 5% GFP+ donor cells. For PU.1 deletion PU.1fl/fl or PU.1fl/fl::MxCre reconstituted mice were intra-peritoneallay injected with 5µg/g Polyinosinic :polycytidylic acid 7 and 9 days prior to control (PBS) or 10µg M-CSF injection. All mouse experiments were performed under specific pathogen-free conditions in accordance with institutional guidelines.   
FACS analysis For FACS sorting and analysis we used described staining protocols3 and published stem and progenitor cell definitions34, FACSCanto, LSRII and FACSAriaIII equipment and DIVATM software (Becton-Dickinson), analysing only populations with at least 200 events. For HSC analysis we used antibodies anti-CD34-FITC (clone RAM34, BD Biosciences), anti-CD135-PE (clone A2F10.1, BD Biosciences), anti-CD150-Pe-Cy7 (clone TC15-12F12.2, Biolegend), anti-CD117-APC-H7 (clone 2B8, BD Biosciences), anti-Sca-1-Pe-Cy5 (clone D7, Biolegend), anti-CD48-APC (clone HM48-1, Biolegend). Diverging from this or in addition we used antibodies anti-CD34 Alexa 700 (clone RAM34, BD Biosciences), anti-CD16/32 PE (clone 2.4G2, BD biosciences), anti-CD11b PE-CF594 (clone M1/70, BD biosciences), anti-CD19PE-Cy7 (clone 1D3, BD biosciences), anti CD45.2 APC (clone 104, BD biosciences) and anti CD45.1 Pacific Blue (clone A20,BD biosciences) for progenitor and blood cell analysis. LIVE/DEAD Fixable Violet Dead cell dye (Invitrogen) was used as viability marker.   
Intra-spleenic injection of sorted HSC and fluorescence microscopy For analysis of HSC in vivo, 1500 to 7000 FACS sorted CD150+ CD34- KSLF HSC were stained 10 min at 37°C with 3µM CFSE (Invitrogen) in PBS / 0,5% BSA, washed 3x in PBS / 0,5% BSA and injected in 30µl PBS (containing or not 1µg of isotype control or AFS98 α-M-CSFR antibody26 or 2µM GW2580, 10µM Ly29400, 10µM PD98059 or 2µM SU6656 inhibitors in 0.9% DMSO) into the spleen of anesthetized mice. After 24h spleens were embedded in OCT (Tissue-Tek, Sakura) and frozen at -80°C. Cryostat sections (5µm) were prepared from the entire organ, dried and fixed 10 min in 4% PFA/PBS at room temperature (RT) and every 10th section was further processed. After washes in PBS, slides were blocked for 1 hour at RT in PBS / 2%BSA/ 1% Donkey serum / 1% FCS / 0.1% saponin, incubated for 36h at 4°C with anti-PU.1 polyclonal antibody (Santa Cruz) in PBS / 0.05% saponin (1:50), washed and incubated with secondary Alexa 546-donkey-anti-rabbit antibody (Molecular probes) in PBS / 0.05% saponin (1:500). All immunofluorescence samples were mounted with ProLong Gold DAPI antifade (Molecular probes) and analyzed by multifluorescent microscopy on a Zeiss Axioplan 2. All CFSE+ cells were analysed for PU.1 expression up to >30 or > 50 cells as indicated. Cell counts and staining were verified by a second trained microscopist blinded to sample identity. High-resolution photographes were obtained by confocal microscopy on a Leica SP5X.   
In vitro culture of HSC CD150+ CD34- KSLF HSC or CD150+ CD34- CD48- KSLF HSC (single cells) were sorted into S-clone SF-03 medium (Sanko Jyunyaku) with 10% FBS supplemented with 100 U/ml penicillin and 100mg/ml streptomycin (both Invitrogen) and cultivated in uncoated U-Shape 96 well plates (Greiner) in 100 µl SCM, 20 ng/ml rSCF, 50 ng/ml rTPO +/- 100 ng/ml rM-CSF or 100 ng/ml rGM-CSF or 100 ng/ml rG-CSF. All cytokines were murine and from PeproTech. Cell viability was analyzed by AnnexinV and Propidium iodide FACS staining35.   
Quantitative real time PCR Total RNA was isolated and reverse transcribed with μMACS One-step T7 template kit (Miltenyi Biotec) and analysed by quantitative real-time PCR using TaqMan Universal PCR Master Mix and a 7500 Fast Real Time PCR System sequence detection system (both Applied Biosystem), following the manufacturers’ instructions.  
Single cell gene expression profiling  Single cells were sorted using the autoclone module on an AriaIII sorter (Becton-Dickinson) directly into 96 wells plate in the CellsDirect Reaction Mix (Invitrogen). Individual cell lysis, cDNA synthetis 
and amplification was performed according to Fluidigm Advanced Development Protocol and single cell microfluidic real time PCR using Dynamic Array IFCs (BiomarkTM Fluidigm) was performed by a technical support specialist of Fluidigm Inc. Preamplified products (22 cycles) were diluted 5-fold prior to analysis with Universal PCR Master Mix and inventoried TaqMan gene expression assays (ABI) in 96.96 Dynamic Arrays on a BioMarkTM System (Fluidigm). Ct values were calculated from the system’s software (BioMarkTM Real-time PCR Analysis; Fluidigm) and filtered according to a set of quality control rules outlined below. Gene filter: (a) For each gene, including controls, data with CtCall = FAILED and CtQuality < threshold were removed. (b) For each gene, including controls, CtValues > = 32.0 were removed to filter out very low expression genes. (c) For each gene, including controls, genes with a difference of duplicate CtValues > = 2.0 were considered inconsistent and removed. Sample filter: (a) If the control gene (Gapdh) was not expressed or was removed according to gene filters (a-c), the whole sample was removed. (b) If the mean of the Ct values of all genes in a row was >= 27.0 the whole sample row was removed.  
Time-Lapse imaging and analysis Wherever possible our video microscopy protocols followed proposed guidelines 24. In detail, FACS sorted CD150+ CD34- KSLF HCS from wt C57/Bl6 or GFP-negative CD150+ CD34- KSLF HSC from PU.1-GFP reporter mouse 31 bone marrow were suspended in SCM supplemented with 100 U/ml penicillin and 100mg/ml streptomycin, 20 ng/ml rSCF, 50 ng/ml rTPO +/- 100 ng/ml rM-CSF and plated in Ibidi μ-slidesVI(0.4) (Biovalley SA, France). Time-lapse microscopy was performed using a Cell Observer system (Carl Zeiss Microscopy GmbH, Germany) at 37°C and 5% CO2. Images were acquired every 10 minutes using 10x (A-plan 10x/0.45 Ph1) or 40x (Plan-Apochromat 40x/0.95 Korr M27) objectives in brightfield and fluorescence (GFP filters: EX BP 470/40; at 350 ms) with a CoolSNAPHQ2 monochrome camera (Photometrics) with a 2x2 binning and a metal halide 120W source for fluorescence illumination. For image analysis a matrix of 4x4 images was acquired for each time point. Images were stitched with AxioVision software (Carl Zeiss Microscopy GmbH, Germany) and processed with Fiji software36 using a slight rolling ball subtraction of background and 1 pixel Gaussian blur. For background subtraction of brightfield images, the median of z-projection was subtracted from the time-lapse stack. Single cell tracking was performed with basic commands of 
ImageJ37 and Fiji36 software and with specific tracking plugin MTrackJ38 in manual mode. Each cell was tracked manually frame-by-frame in the bright field channel and cross-controlled by two microscope specialists. Cells with non-standard morphology or size were rejected. The fluorescence signal was measured as the difference of maximum minus minimum intensity within a defined region of interest (ROI) around each cell. Cell properties and behaviour (cell division, cell death, position, fluorescence increase) were manually documented to build cumulated curves. R39 and Excel (Microsoft Corporation) software was used to manage data and build graphics.  
Statistical analysis P values were calculated by two-tailed non parametric Mann-Witney test for direct sample comparisons or Pearson’s chi2 test for proportions (alpha=0,05). Whisker plots show median (lines), upper and lower quartiles (boxes) and extreme outliers (dotted whiskers).   
Methodes References  31 Back, J., Dierich, A., Bronn, C., Kastner, P. & Chan, S. PU.1 determines the self-renewal capacity of erythroid progenitor cells. Blood 103, 3615-3623 (2004). 32 Dakic, A. et al. PU.1 regulates the commitment of adult hematopoietic progenitors and restricts granulopoiesis. J Exp Med 201, 1487-1502 (2005). 33 Okabe, M., Ikawa, M., Kominami, K., Nakanishi, T. & Nishimune, Y. 'Green mice' as a source of ubiquitous green cells. FEBS Lett 407, 313-319 (1997). 34 Bryder, D., Rossi, D. J. & Weissman, I. L. Hematopoietic stem cells: the paradigmatic tissue-specific stem cell. Am J Pathol 169, 338-346 (2006). 35 Niu, C. et al. c-Myc is a target of RNA-binding motif protein 15 in the regulation of adult hematopoietic stem cell and megakaryocyte development. Blood 114, 2087-2096(2009). 36 Schindelin, J., Proceedings of the ImageJ conference(2008). 37 Rasband, W.S.,ImageJ, http://imagej.nih.gov/ij/ (Bethesda, ML, USA, 1997-2012). 38 Meijering, E., Dzyubachyk, O. & Smal, I. Methods for cell and particle tracking. Methods Enzymol 
504, 183-200 (2012). 39 R: A language and environment for statistical computing (Vienna, Austria, 2012).  
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Sup.table 1, related to Fig 3a,b,c
Summary of cell numbers with myeloid identity in three independent single cell nano-fluidic real time 
PCR experiments on FluidigmTM array for freshly isolated HSC (0h) or after 16 hour of culture in the 
absence or the presence of M-CSF. HSC were FACS sorted as CD150+CD34-CD48-KSLF 
(experiment 1,3) or CD150+CD34-KSLF (experiment 2). Experiment 3 is shown in Fig.3a and 
sup.Fig.7-9.
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Sup.Fig.1 Effect of LPS on M-CSF release and PU.1 induction in HSC
a) Serum levels of M-CSF after LPS stimulation
Median and individual concentrations of M-CSF in blood serum from five mice 
at the indicated times after 5mg/kg intra-peritoneal LPS injection.
b,c)Representative FACS profiles (b) and quantification (c) of GFP expression 
in MPP and HSC of PU.1-GFP reporter mice before or after 24h of 5mg/kg LPS 
injection. 
** p = 0.03, n = 4,2
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Sup.Fig.2 M-CSFR expression in HSC
Relative expression of M-CSFR normalized to GAPDH 
(R.U.) by qRT-PCR analysis in sorted HSC, KSL 
(c-kit+, sca-1+, lin–) hematopoietic stem and progeni-
tor cells (HS/PC) and CD19+ B-cells from the bone 
marrow, as positive and negative control respectively. 
Error bars show standard error of the mean from dupli-
cates. Error Bars show standard deviation from dupli-
cates.
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Sup.Fig.3 M-CSFR and MafB expression in HSC after M-CSF 
stimulation 
Relative expression of M-CSFR (a) and MafB (b) normalized to 
GAPDH (R.U.) by qRT-PCR analysis in sorted HSC, 16h after 
control (PBS) or M-CSF injection, compared to untreated MPP 
(CD135+ KSL) as control for a population containing myeloid 
committed cells3, with high M-CSFR and low MafB expression, 
respectively. Error bars show standard deviation from duplicates.
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Sup.Fig.4 Distribution of CD150hi HSC in GFP+ HSC.
a) Gating strategy for CD150hi HSC in the KSL compartment following published 
definitions20.
b,c) Representative FACS profiles (b) and quantification (c) of CD150hi HSC subpopula-
tions in GFP+ and GFP- HSC from PU.1-GFP mice 16h after control (PBS) or M-CSF 
injection.
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Sup.Fig.5 Recording of cell division and cell death of HSC in culture by video imaging. 
Cumulative cell divisions (left) and cumulative number of cells that died (right) of CD150hi (a) and 
total (b) HSC for 100 and 360 input cells respectively, over the indicated times in culture with or 
without M-CSF. The vast majority of first cell divisions occurred after 24h and nearly no additional 
cell death occurred after minimal initial sorting and culture stress. No significant differences in 
proliferation or cell death were detected between culture with or without M-CSF. 
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Sup.Fig.6 Analysis of viability of HSC after M-CSF stimu-
lation 
Propidium iodide / Annexin V staining of HSC after 16h in 
culture with or without M-CSF.
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Sup.Fig.7 Blow up of Fig.3a, 
showing single cell gene expres-
sion analysis of HSC before culture.
The genes analyzed are classified and 
colour coded on top according to 
published gene expression analysis of 
early lineage committed 
progenitors40,41. PU.1 is indicated by an 
asterix. Cells are clustered according 
to lineage identity indicated on the 
right.
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Sup.Fig.8 Blow up of Fig.3b, 
showing single cell gene expres-
sion analysis of HSC after 16h 
culture without M-CSF. 
The genes analyzed are classified and 
colour coded on top according to 
published gene expression analysis of 
early lineage committed 
progenitors40,41. PU.1 is indicated by an 
asterix. Cells are clustered according 
to lineage identity indicated on the 
right.
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Sup.Fig.9 Blow up of Fig.3c, 
showing single cell gene expression 
analysis of HSC after 16h culture 
with M-CSF. 
The genes analyzed are classified and 
colour coded on top according to 
published gene expression analysis of 
early lineage committed 
progenitors40,41. PU.1 is indicated by an 
asterix. Cells are clustered according 
to lineage identity indicated on the 
right.
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Sup.Fig.10 Differentiation potential of M-CSF induced PU.1+ cells
a) Experimental design for transplantation of sorted CD45.2 PU.1- HSC before and after 
induction of PU.1+ cells in M-CSF culture into sub-lethally irradiated CD45.1 recipients and 
analysis of progeny cells after 2 weeks in the spleen.
b,c) Quantification of the ratio of donor GMP to MEP progenitors (b) and total GMP (c) 
derived from transplanted PU.1- HSC before or PU.1+ cells after M-CSF culture. **p = 0.02, 
*p = 0.07, n = 6,7.
d) Cells with macrophage morphology phagocytosing fluorescent latex beads after conti-
nued culture of PU.1+ cells in M-CSF for 10 days.
CD45.1 
a
CD45.2 GMP + MEP in spleen (2w)
CD45.2 Myelo/Lympho in blood (4w)
b
0
10
20
30
1
4
16
64
256
1024
+- M-CSF+- M-CSF+-
%
 in
 C
D
45
.2
 c
el
ls
ra
tio
Monocytes/B-cellsGMP
c
 
M-CSF 
16h 
CD45.2
HSC 
*** ***
MEP
Spleen Blood
Sup.Fig.11 Differentiation potential of M-CSF primed HSC
a) Experimental design for transplantation of in vivo M-CSF primed CD45.2 
HSC into sub-lethally irradiated CD45.1 recipients and analysis of progeny 
cells after 2 weeks in the spleen or 4 weeks in the blood.
b) Percentage of GMP and MEP progenitors in total donor cells derived 
from control (PBS) or M-CSF primed HSC in the spleen 2 weeks after trans-
plantation. 
*p = 0.1, **p = 0.04, n = 4,4
c) Quantification of the ratio of donor CD11b+ SSClo monocytes to CD19+ 
B-cells in the blood 4 weeks after transplantation. ***p = 0.009, n = 8,4.
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Sup.Fig.12 Competitive transplantation of M-CSF primed HSC
a) Experimental design for competitive transplantation of FACS sorted in 
vivo M-CSF primed HSC (CD150+CD34-CD135-KSL) from actin-GFP 
CD45.2 mice together with CD45.2 competitor HSC into lethally irradiated 
CD45.1 recipients and analysis of blood cell contribution.
b) Gating strategy for quantification of actin-GFP+ HSC derived myeloid , 
lymphoid blood cells and platelets. 
sup. fig.12.
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Sup.Fig.12 Competitive transplantation of M-CSF primed HSC
c) Donor contribution to blood of competitively reconstituted mice 4, 6 and 14 weeks after transplantation of 
M-CSF primed or control HSC, expressed as percentage of GFP+ donor cells in Mac+ myeloid, CD19+ B Cells, 
CD61+ Platelets (4, 6 and 14 weeks) and CD3e T Cells (14 weeks) and normalized to total GFP contribution in 
CD45.2 donor compartment. ** p = 0.03, n = 6,4.
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Sup.Fig.13 Analysis of PU-1 deletion
PCR analysis to detect deleted (PU.1Δ) and loxP flanked 
(PU.1fl) PU.1 alleles in samples transplanted in fig.4i from 
control or M-CSF primed HSC isolated from PU.1fl/fl::MxCre 
or PU.1fl/fl bone marrow 7 days after last treatment with pI:C.
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Sup.Fig.14 Gating strategy for detection of HSC derived donor CD45.2 GMP and MEP 
populations in the spleens of CD45.1 recipients.
